Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GeoVax Hepatitis B Therapeutic
- Development stage
- Preclinical
- Lead developer
- GeoVax Labs
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GeoVax's Hepatitis B therapeutic vaccine is an investigational immunotherapy designed to treat chronic hepatitis B virus (HBV) infection. Developed using GeoVax's proprietary Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) platform in collaboration with Georgia State University, the vaccine utilizes a modified vaccinia Ankara (MVA) viral vector to encode specific HBV antigens. Upon administration, the vector induces the patient's own cells to produce self-assembling, non-infectious virus-like particles (VLPs). This approach is engineered to trigger a comprehensive immune response, including both neutralizing antibodies (humoral) and T-cell mediated (cellular) activity, aiming to overcome the immune tolerance or exhaustion characteristic of chronic HBV. The candidate is intended to be used potentially as a monotherapy or as part of a combination regimen with standard-of-care antivirals to achieve a functional cure for the millions of individuals living with chronic HBV.
- Other names
- MVA-VLP HBV vaccine
02
Targets
HBV antigens (Hepatitis B virus antigens)
Beyond the preview
Go deeper on GeoVax Hepatitis B Therapeutic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeoVax Hepatitis B Therapeutic.